283 related articles for article (PubMed ID: 23577226)
1. The involvement of NRF2 in lung cancer.
Bauer AK; Hill T; Alexander CM
Oxid Med Cell Longev; 2013; 2013():746432. PubMed ID: 23577226
[TBL] [Abstract][Full Text] [Related]
2. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
[TBL] [Abstract][Full Text] [Related]
3. A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy.
Zhang D; Hou Z; Aldrich KE; Lockwood L; Odom AL; Liby KT
Mol Cancer Ther; 2021 Sep; 20(9):1692-1701. PubMed ID: 34158350
[TBL] [Abstract][Full Text] [Related]
4. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.
Solis LM; Behrens C; Dong W; Suraokar M; Ozburn NC; Moran CA; Corvalan AH; Biswal S; Swisher SG; Bekele BN; Minna JD; Stewart DJ; Wistuba II
Clin Cancer Res; 2010 Jul; 16(14):3743-53. PubMed ID: 20534738
[TBL] [Abstract][Full Text] [Related]
5. [Nrf2 and Keap1 Abnormalities in 104 Lung Adenocarcinoma Cases and Association with Clinicopathologic Features].
Xiao Y; Zhu X; Gu Y; Chen S; Liang L; Cao B
Zhongguo Fei Ai Za Zhi; 2018 Mar; 21(3):241-250. PubMed ID: 29587953
[TBL] [Abstract][Full Text] [Related]
6. Targeting the cell signaling pathway Keap1-Nrf2 as a therapeutic strategy for adenocarcinomas of the lung.
Zhang B; Ma Z; Tan B; Lin N
Expert Opin Ther Targets; 2019 Mar; 23(3):241-250. PubMed ID: 30556750
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution.
Taguchi K; Motohashi H; Yamamoto M
Genes Cells; 2011 Feb; 16(2):123-40. PubMed ID: 21251164
[TBL] [Abstract][Full Text] [Related]
8. Role of NRF2 in Lung Cancer.
Sánchez-Ortega M; Carrera AC; Garrido A
Cells; 2021 Jul; 10(8):. PubMed ID: 34440648
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
10. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy.
Singh A; Boldin-Adamsky S; Thimmulappa RK; Rath SK; Ashush H; Coulter J; Blackford A; Goodman SN; Bunz F; Watson WH; Gabrielson E; Feinstein E; Biswal S
Cancer Res; 2008 Oct; 68(19):7975-84. PubMed ID: 18829555
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of the Nrf2-Keap1 signaling pathway in cancer.
Jaramillo MC; Zhang DD
Genes Dev; 2013 Oct; 27(20):2179-91. PubMed ID: 24142871
[TBL] [Abstract][Full Text] [Related]
12. Keap1-Nrf2 Interaction Suppresses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein.
Chien MH; Lee WJ; Hsieh FK; Li CF; Cheng TY; Wang MY; Chen JS; Chow JM; Jan YH; Hsiao M; Hua KT; Kuo ML
Clin Cancer Res; 2015 Oct; 21(20):4719-32. PubMed ID: 26078391
[TBL] [Abstract][Full Text] [Related]
13. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
[TBL] [Abstract][Full Text] [Related]
14. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth.
Zhang P; Singh A; Yegnasubramanian S; Esopi D; Kombairaju P; Bodas M; Wu H; Bova SG; Biswal S
Mol Cancer Ther; 2010 Feb; 9(2):336-46. PubMed ID: 20124447
[TBL] [Abstract][Full Text] [Related]
15. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
16. Nrf2 protects against airway disorders.
Cho HY; Kleeberger SR
Toxicol Appl Pharmacol; 2010 Apr; 244(1):43-56. PubMed ID: 19646463
[TBL] [Abstract][Full Text] [Related]
17. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer.
Hayes JD; McMahon M
Trends Biochem Sci; 2009 Apr; 34(4):176-88. PubMed ID: 19321346
[TBL] [Abstract][Full Text] [Related]
18. Toward clinical application of the Keap1-Nrf2 pathway.
Suzuki T; Motohashi H; Yamamoto M
Trends Pharmacol Sci; 2013 Jun; 34(6):340-6. PubMed ID: 23664668
[TBL] [Abstract][Full Text] [Related]
19. Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents.
Magesh S; Chen Y; Hu L
Med Res Rev; 2012 Jul; 32(4):687-726. PubMed ID: 22549716
[TBL] [Abstract][Full Text] [Related]
20. Molecular effects of cancer-associated somatic mutations on the structural and target recognition properties of Keap1.
Khan H; Killoran RC; Brickenden A; Fan J; Yang D; Choy WY
Biochem J; 2015 Apr; 467(1):141-51. PubMed ID: 25582950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
